Suppliers and packagers for MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
B Braun Medical	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	meropenem	POWDER;INTRAVENOUS	202106	NDA	B. Braun Medical Inc.	0264-3183-11	24 CONTAINER in 1 CASE (0264-3183-11) / 50 mL in 1 CONTAINER	2015-04-30
B Braun Medical	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	meropenem	POWDER;INTRAVENOUS	202106	NDA	B. Braun Medical Inc.	0264-3185-11	24 CONTAINER in 1 CASE (0264-3185-11) / 50 mL in 1 CONTAINER	2015-04-30

Suppliers and packagers for MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

Last updated: June 8, 2026

Suppliers for Meropenem and Sodium Chloride in a Duplex Container (Reconstitution, Packaging, and Distribution)

Meropenem in hospital supply is typically delivered as a sterile lyophilized vial plus a separate solvent product, most commonly 0.9% sodium chloride injection. “Duplex” container configurations (paired container systems for reconstitution) depend on the manufacturer’s device and fill-finish packaging line, not on a single universal supply chain. The practical supplier set therefore splits into (1) meropenem drug substance and drug product manufacturers, (2) 0.9% sodium chloride injection suppliers, and (3) duplex container system vendors and packaging/fill-finish partners that assemble or co-pack the final presentation for specific SKUs.

What companies supply meropenem (lyophilized) vials for duplex or dual-container reconstitution?

Meropenem API and finished dose supply chain

In duplex-container hospital systems, the finished meropenem product usually arrives as:

• Lyophilized meropenem sterile powder in a vial
• A reconstitution workflow that uses 0.9% sodium chloride injection to prepare an IV dose

Supply sources typically include:

• Brand and originator supply channels (in markets where the originator remains marketed)
• Generic sterile injectable suppliers with lyophilization capability and strict aseptic fill-finish controls

Key supplier categories

• API manufacturers: supply meropenem bulk drug substance under contract or via vertically integrated sterile injectable producers.
• Drug product manufacturers: lyophilize meropenem drug product, package in vials, and deliver to distributors.
• Co-pack and assembly partners: handle final kit configuration (where permitted) and ensure cold-chain and device compatibility.

What suppliers provide 0.9% sodium chloride injection for duplex container reconstitution?

Sodium chloride injection supply chain

For duplex container presentations, the sodium chloride component is almost always:

• 0.9% sodium chloride injection, sterile
• Supplied in a compatible container type for the kit design (commonly flexible bags or rigid containers depending on the system architecture)

Supply sources include:

• Established sterile IV solution manufacturers
• Co-packers that assemble IV solution and drug vials into a single carton/kit

Container-compatibility gating

Duplex systems depend on:

• Compatibility of the sodium chloride container closure with the drug-transfer interface
• Chemical and mechanical compatibility with the meropenem reconstitution device
• Regulatory labeling and traceability for the reconstituted product workflow

Which suppliers make the “duplex container” reconstitution system (device and packaging)?

Device-driven supply chain

The term “duplex container” usually maps to kit or reconstitution system architecture that couples:

• A drug vial (meropenem)
• A solvent container (0.9% sodium chloride)
• A transfer/reconstitution interface that supports aseptic handling and accurate dose preparation

Supplier types:

• Packaging device manufacturers: produce the container pair, interfaces, and assembly components.
• Fill-finish and kit assembly houses: assemble the duplex system and perform final packaging under GMP.

Validation requirements

Duplex suppliers need:

• Extractables and leachables assessments for the container-contact materials
• Sterility assurance and bioburden controls for the assembled kit
• Compatibility data for meropenem with the sodium chloride container and reconstitution workflow

Who are the typical co-packers and sterile packaging/kit assemblers for hospital IV duplex systems?

Contract sterile packaging and kit assembly

In practice, the “duplex” presentation often results from:

• A drug product supplier (meropenem vial) plus
• An IV solutions supplier (0.9% NaCl container)
• A contract packaging/assembly partner that consolidates the kit and prints SKU-level labeling

Contract assemblers are selected based on:

• Line clearance and assembly protocol
• Traceability and lot genealogy
• Ability to maintain compliance for all components through distribution

What patent or regulatory status affects supplier selection for meropenem + sodium chloride duplex kits?

Regulatory product definition drives sourcing

Even when the device is “kit-like,” FDA approval status is SKU-specific:

• Meropenem drug product regulatory status determines vial formulation, potency specifications, and labeling.
• Sodium chloride injection regulatory status determines solution container system and labeling.
• The combined “kit” presentation, if marketed as such, depends on how the kit is defined and registered.

Practical implication for procurement

Supplier selection is constrained by:

• Lot-level traceability requirements (audit readiness for hospitals and government procurement)
• Device quality systems (because duplex interfaces become part of the marketed presentation)

How many supplier options exist for duplex-configured meropenem + 0.9% sodium chloride in the US/EU?

Supplier mapping logic

Because duplex systems are device- and SKU-dependent, the count of eligible suppliers in a region is determined by:

• Whether the meropenem SKU is manufactured by a supplier licensed for that presentation
• Whether the sodium chloride SKU and container are compatible with the duplex interface
• Whether a co-packer can assemble and label the kit at GMP level

In many markets, the number of true duplex-configuration SKUs is smaller than the number of standalone meropenem vials and standalone sodium chloride injections.

What generic entry risks exist for duplex meropenem products?

Risk categories

• Drug product substitution risk: meropenem vial generics vary in excipients, lyophilization process, and reconstitution behavior.
• Solvent container risk: different sodium chloride container systems can change transfer dynamics and hold-up volume.
• Kit assembly risk: an assembly partner error can create traceability and sterility assurance issues.

Procurement mitigation

Purchasers mitigate by:

• Validating reconstitution time, clarity criteria, and compatibility
• Confirming kit-specific IFU and labeling match facility workflow

How does meropenem duplex supply compare with standalone reconstitution supply (vials + sodium chloride bags)?

Operational differences

• Duplex kits reduce pick-and-mix steps on the nursing floor.
• Standalone reconstitution increases handling steps and inventory complexity.

IP and compliance

• Standalone components still require compliance for each component SKU.
• Duplex kits add device interface and assembly responsibility.

Where are supply-chain bottlenecks for meropenem duplex kits most likely to occur?

Bottleneck points

• Lyophilization capacity for meropenem sterile powder
• Aseptic fill-finish capacity for high-risk sterile injectables
• Availability of compatible sodium chloride container formats for the duplex interface
• Kit assembly line capacity and validated transfer interface supply

What due diligence should buyers use to qualify duplex kit suppliers?

Minimum qualification package

• GMP compliance evidence for drug product and for sterile solutions
• Lot genealogy documentation across vial, solution, and kit assembly
• Device quality documentation for the duplex interface and closure system
• Compatibility and stability evidence consistent with the marketed instructions for use

Key Takeaways

• Duplex container presentations for meropenem + sodium chloride depend on a multi-party supply chain: meropenem vial manufacturers, 0.9% sodium chloride injection suppliers, and kit assembly/device providers.
• The limiting factor is not only drug and solvent availability, but container interface compatibility, kit assembly GMP capability, and SKU-level regulatory definition.
• Supplier qualification must be SKU-specific because duplex interfaces and labeling create compliance and traceability obligations beyond standalone reconstitution components.

FAQs

1. What delivery formats are used for meropenem kits that rely on 0.9% sodium chloride reconstitution?
2. How do container and closure systems for sodium chloride affect duplex kit reconstitution and handling?
3. What GMP evidence is required from kit assemblers for duplex-container hospital IV products?
4. Do generic meropenem vials require compatibility re-verification with the same sodium chloride duplex interfaces?
5. What documentation should procurement request to ensure lot traceability across vial, solvent, and kit assembly?

References

1. FDA. Approved Drug Products and Approved Drug Labels (Orange Book and labeling resources). US FDA.
2. EMA. European public assessment reports and product information for sterile medicinal products. European Medicines Agency.
3. USP. <1> Biological Reactivity Tests; <71> Sterility Tests; <85> Bacterial Endotoxins Test. United States Pharmacopeia.